AU Patent

AU2015311674A1 — Secnidazole for use in the treatment of bacterial vaginosis

Assigned to Evofem Biosciences Inc · Expires 2017-03-09 · 9y expired

What this patent protects

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). Embodiments described herein are directed to a method of treating bacterial vaginosis in a subject in need thereof comprising administeri…

USPTO Abstract

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). Embodiments described herein are directed to a method of treating bacterial vaginosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation. In some embodiments, the secnidazole in a microgranule formulation is administered orally. In some embodiments, the secnidazole in a microgranule formulation comprises a plurality of microgranules.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015311674A1
Jurisdiction
AU
Classification
—
Expires
2017-03-09
Drug substance claim
No
Drug product claim
No
Assignee
Evofem Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.